NEW DELHI: Those who have recovered from Covid-19, respond faster to the Covishield vaccine and reach high antibody levels, according to a study on Covishield vaccine. It leads to hopes that they may not need a second dose and therefore, help widen India’s corona immunisation cover.
The study on Covishield’s immune response was carried out by researchers from New Delhi’s CSIR-Institute of Genomics and Integrative Biology (IGIB), Max Super Specialty Hospital and Institute of Endocrinology, Diabetes and Metabolism as well as the Academy of Scientific and Innovative Research (AcSIR) in Ghaziabad.
Researchers involved in the study and CSIR-IGIB Director Anurag Aggarwal said that a strong immune response from Covishield has been observed. In those who are seropositive in origin, the reaction is rapid and antibodies reach high levels.
Seropositivity is an indicator of the presence of the virus in the serum, or evidence of previous exposure to it.
The Oxford-AstraZeneca’s Covid 19 vaccine, or ChAdOx, is an important part of the global vaccine roll-out. Covishield, a locally manufactured version by Pune’s Serum Institute of India, is one of the two vaccines along with the indigenous Covaxin, from the Hyderabad-based company Bharat Biotech, approved for use in the country.